Real-World Treatment Patterns in Patients with Spinal Muscular Atrophy Receiving Multiple Disease-Modifying Therapies. (PubMed, Adv Ther) - Sep 27, 2026 - "Following widespread NBS, OAV had the highest utilization among patients age ≤ 2 years as first or second DMT after nusinersen or risdiplam. Use of a second DMT type was lowest among patients who initiated OAV."
HEOR • Journal • Real-world evidence • Genetic Disorders • Movement Disorders • Muscular Atrophy • Rare Diseases
|
|
Dongni Ye; Esteban Lemus Wirtz; John Meehan; Min Yang; Sandra Reyna; Walter Toro Jimenez; Wei Song
|